The Effectiveness of Risankizumab Following Guselkumab Failure in Moderate-to-Severe Psoriasis Patients: A Retrospective Study.

Hamm, Camille; Ramsoondar, Nusha; McGillis, Michaela; Waugh, Miranda; Gooderham, Melinda; Giroux, Lyne L

Hamm, Camille; Ramsoondar, Nusha; McGillis, Michaela; Waugh, Miranda; Gooderham, Melinda; Giroux, Lyne L.

Afiliación

Hamm C; The Ottawa Hospital Division of Dermatology, Ottawa, Canada.
Ramsoondar N; Northern Ontario School of Medicine University, Undergraduate Medical Education, Canada.
McGillis M; Northern Ontario School of Medicine University, Undergraduate Medical Education, Canada.
Waugh M; The Ottawa Hospital Division of Dermatology, Ottawa, Canada.
Gooderham M; Department of Medicine, Queen's University, Kingston, Canada.
Giroux LL; SKiN Centre for Dermatology, Peterborough, United Kingdom.

J Cutan Med Surg ; 27(5): 476-480, 2023.

Article en En | MEDLINE | ID: mdl-37559454

Asunto(s)

Anticuerpos Monoclonales; Psoriasis; Humanos; Estudios Retrospectivos; Interleucina-23; Psoriasis/inducido químicamente; Resultado del Tratamiento; Enfermedad Crónica; Índice de Severidad de la Enfermedad

Palabras clave

biologics; guselkumab; interleukin-23 inhibitors; psoriasis; risankizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Psoriasis / Anticuerpos Monoclonales Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: J Cutan Med Surg Asunto de la revista: DERMATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google